Clinical Research Directory
Browse clinical research sites, groups, and studies.
A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults
Sponsor: Regeneron Pharmaceuticals
Summary
This clinical study will evaluate the study drug, REGN22044, in healthy participants. REGN22044 has not previously been studied in humans. The purpose of this study is to learn: * What side effects may happen when REGN22044 is taken * How much of REGN22044 is in the blood at different times * Whether the body makes antibodies against REGN22044 (which could make the drug less effective or could lead to side effects)
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN22044 in Healthy Adult Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
88
Start Date
2026-06-05
Completion Date
2027-02-08
Last Updated
2026-08-25
Healthy Volunteers
Yes
Conditions
Interventions
REGN22044
Administered per the protocol
Placebo
Administered per the protocol
Locations (1)
Ghent University Hospital
Ghent, Oost-Vlaanderen, Belgium